Protein post-translational modification in host defense: The antimicrobial mechanism of action of human eosinophil cationic protein native forms

FEBS Journal

Volumn 281, Issue 24, 2014, Pages 5432-5446

  Salazar, Vivian A ^a   Rubin, Jenny ^b   Moussaoui, Mohammed ^a   Pulido, David ^a   Nogués, Maria Victòria ^a   Venge, Per ^b   Boix, Ester ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Agglutination; Antimicrobial proteins; Glycosylation; Immunity; Membrane

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; EOSINOPHIL CATIONIC PROTEIN; RECOMBINANT PROTEIN; RNASE3 PROTEIN, HUMAN;

ANTIMICROBIAL ACTIVITY; ARTICLE; ARTIFICIAL MEMBRANE; BACTERIAL MEMBRANE; BINDING AFFINITY; CELL AGGLUTINATION; CONTROLLED STUDY; ESCHERICHIA COLI; HOST RESISTANCE; MEMBRANE DAMAGE; MEMBRANE DEPOLARIZATION; MOLECULAR WEIGHT; NONHUMAN; PROTEIN AGGREGATION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN PURIFICATION; DRUG EFFECTS; GLYCOSYLATION; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY;

EOSINOPHIL CATIONIC PROTEIN; ESCHERICHIA COLI; GLYCOSYLATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84916235784     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13082     Document Type: Article

References (70)

1. Hewitson JP, Grainger JR & Maizels RM (2009) Helminth immunoregulation: the role of parasite secreted proteins in modulating host immunity. Mol Biochem Parasitol 167, 1-11.
2. Shamri R, Xenakis JJ & Spencer LA (2011) Eosinophils in innate immunity: an evolving story. Cell Tissue Res 343, 57-83.
3. Rosenberg HF, Dyer KD & Foster PS (2013) Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 13, 9-22.
4. Simon D, Simon HU & Yousefi S (2013) Extracellular DNA traps in allergic, infectious, and autoimmune diseases. Allergy 68, 409-416.
5. Akuthota P, Xenakis JJ & Weller PF (2011) Eosinophils: offenders or general bystanders in allergic airway disease and pulmonary immunity? J Innate Immun 3, 113-119.
6. Ackerman SJ, Gleich GJ, Loegering DA, Richardson BA & Butterworth AE (1985) Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of schistosoma mansoni. Am J Trop Med Hyg 34, 735-745.
7. Boix E, Salazar VA, Torrent M, Pulido D, Nogués MV & Moussaoui M (2012) Structural determinants of the eosinophil cationic protein antimicrobial activity. Biol Chem 393, 801-815.
8. Malik A & Batra JK (2012) Antimicrobial activity of human eosinophil granule proteins: involvement in host defence against pathogens. Crit Rev Microbiol 38, 168-181.
9. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ & Gleich GJ (1989) Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 142, 4428-4434.
10. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L & Trulson A (1999) Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 29, 1172-1186.
11. Bystrom J, Amin K & Bishop-Bailey D (2011) Analysing the eosinophil cationic protein - a clue to the function of the eosinophil granulocyte. Respir Res 12, 10.
12. Beintema JJ & Kleineidam RG (1998) The ribonuclease a superfamily: general discussion. Cell Mol Life Sci 54, 825-832.
13. Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ & McKean DJ (1986) Biochemical and functional similarities between human eosinophilderived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A 83, 3146-3150.
14. Eriksson J, Woschnagg C, Fernvik E & Venge P (2007) A SELDI-TOF MS study of the genetic and posttranslational molecular heterogeneity of eosinophil cationic protein. J Leukoc Biol 82, 1491-1500.
15. Woschnagg C, Rubin J & Venge P (2009) Eosinophil cationic protein (ECP) is processed during secretion. J Immunol 183, 3949-3954.
16. Zhang J & Rosenberg HF (2000) Sequence variation at two eosinophil-associated ribonuclease loci in humans. Genetics 156, 1949-1958.
17. Jonsson UB, Bystrom J, Stalenheim G & Venge P (2002) Polymorphism of the eosinophil cationic proteingene is related to the expression of allergic symptoms. Clin Exp Allergy 32, 1092-1095.
18. Trulson A, Bystrom J, Engstrom A, Larsson R & Venge P (2007) The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy 37, 208-218.
19. Munthe-Kaas MC, Gerritsen J, Carlsen KH, Undlien D, Egeland T, Skinningsrud B, Torres T & Carlsen KL (2007) Eosinophil cationic protein (ECP) polymorphisms and association with asthma, s-ECP levels and related phenotypes. Allergy 62, 429-436.
20. Eriksson J, Reimert CM, Kabatereine NB, Kazibwe F, Ireri E, Kadzo H, Eltahir HB, Mohamed AO, Vennervald BJ & Venge P (2007) The 434(G>C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection. Int J Parasitol 37, 1359-1366.
21. Rubin J, Zagai U, Blom K, Trulson A, Engstrom A & Venge P (2009) The coding ECP 434(G>C) gene polymorphism determines the cytotoxicity of ECP but has minor effects on fibroblast-mediated gel contraction and no effect on RNase activity. J Immunol 183, 445-451.
22. Glimelius I, Rubin J, Fischer M, Molin D, Amini RM, Venge P & Enblad G (2011) Effect of eosinophil cationic protein (ECP) on Hodgkin lymphoma cell lines. Exp Hematol 39, 850-858.
23. Rubin J & Venge P (2013) Asparagine-linked glycans determine the cytotoxic capacity of eosinophil cationic protein (ECP). Mol Immunol 55, 372-380.
24. Plager DA, Davis MDP, Andrews AG, Coenen MJ, George TJ, Gleich GJ & Leiferman KM (2009) Eosinophil ribonucleases and their cutaneous lesion-forming activity. J Immunol 183, 4013-4020.
25. Beintema JJ, Blank A, Schieven GL, Dekker CA, Sorrentino S & Libonati M (1988) Differences in glycosylation pattern of human secretory ribonucleases. Biochem J 255, 501-505.
26. Sorrentino S (2010) The eight human 'canonical' ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. FEBS Lett 584, 2194-2200.
27. Rosenberg HF (2008) Eosinophil-derived neurotoxin/ RNase 2: connecting the Past, the Present and the Future. Curr Pharm Biotechnol 9, 135-140.
28. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS et al. (2006) Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12, 432-441.
29. Ulrich M, Petre A, Youhnovski N, Promm F, Schirle M, Schumm M, Pero RS, Doyle A, Checkel J, Kita H et al. (2008) Post-translational tyrosine nitration of eosinophil granule toxins mediated by eosinophil peroxidase. J Biol Chem 283, 28629-28640.
30. Hofsteenge J, Muller DR, Debeer T, Loffler A, Richter WJ & Vliegenthart JFG (1994) New-type of linkage between a carbohydrate and a protein - C-glycosylation of a specific tryptophan residue in human Rnase U-S. Biochemistry 33, 13524-13530.
31. Julenius K (2007) NetCGlyc 1.0: prediction of mammalian C-mannosylation sites. Glycobiology 17, 868-876.
32. Marth JD & Grewal PK (2008) Mammalian glycosylation in immunity. Nat Rev Immunol 8, 874-887.
33. Kolarich D, Lepenies B & Seeberger PH (2012) Glycomics, glycoproteomics and the immune system. Curr Opin Chem Biol 16, 214-220.
34. North SJ, von Gunten S, Antonopoulos A, Trollope A, MacGlashan DW, Jang-Lee J, Dell A, Metcalfe DD, Kirshenbaum AS, Bochner BS et al. (2012) Glycomic analysis of human mast cells, eosinophils and basophils. Glycobiology 22, 12-22.
35. Barboza M, Pinzon J, Wickramasinghe S, Froehlich JW, Moeller I, Smilowitz JT, Ruhaak LR, Huang JC, Lonnerdal B, German JB et al. (2012) Glycosylation of human milk lactoferrin exhibits dynamic changes during early lactation enhancing its role in pathogenic bacteria-host interactions. Mol Cell Proteomics 11, 1-28.
36. Krachler AM & Orth K (2013) Targeting the bacteriahost interface: strategies in anti-adhesion therapy. Virulence 4, 284-294.
37. Huang CY, Hsu JT, Chung PH, Cheng WTK, Jiang YN & Ju YT (2013) Site-specific N-Glycosylation of caprine lysostaphin restricts its bacteriolytic activity toward staphylococcus aureus. Anim Biotechnol 24, 129-147.
38. Kren V & Rezanka T (2008) Sweet antibiotics - the role of glycosidic residues in antibiotic and antitumor activity and their randomization. FEMS Microbiol Rev 32, 858-889.
39. Boix E, Nikolovski Z, Moiseyev GP, Rosenberg HF, Cuchillo CM & Nogues MV (1999) Kinetic and product distribution analysis of human eosinophil cationic protein indicates a subsite arrangement that favors exonuclease-type activity. J Biol Chem 274, 15605-15614.
40. Pulido D, Moussaoui M, Andreu D, Nogues MV, Torrent M & Boix E (2012) Antimicrobial action and cell agglutination by the eosinophil cationic protein are modulated by the cell wall lipopolysaccharide structure. Antimicrob Agents Chemother 56, 2378-2385.
41. Torrent M, Pulido D, Nogués MV & Boix E (2012) Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation. PLoS Pathog 8, e1003005.
42. Torrent M, Badia M, Moussaoui M, Sanchez D, Nogues MV & Boix E (2010) Comparison of human RNase 3 and RNase 7 bactericidal action at the Gram-negative and Gram-positive bacterial cell wall. FEBS J 277, 1713-1725.
43. Torrent M, Cuyas E, Carreras E, Navarro S, Lopez O, de la Maza A, Nogues MV, Reshetnyak YK & Boix E (2007) Topography studies on the membrane interaction mechanism of the eosinophil cationic protein. Biochemistry 46, 720-733.
44. Torrent M, de la Torre BG, Nogues VM, Andreu D & Boix E (2009) Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochem J 421, 425-434.
45. Rausch JM, Marks JR, Rathinakumar R & Wimley WC (2007) beta-Sheet pore-forming peptides selected from a rational combinatorial library: mechanism of pore formation in lipid vesicles and activity in biological membranes. Biochemistry 46, 12124-12139.
46. Krauson AJ, He J & Wimley WC (2012) Gain-offunction analogues of the pore-forming peptide melittin selected by orthogonal high-throughput screening. J Am Chem Soc 134, 12732-12741.
47. Wimley WC, Selsted ME & White SH (1994) Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci 3, 1362-1373.
48. Young JD, Peterson CG, Venge P & Cohn ZA (1986) Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 321, 613-616.
49. Torrent M, Odorizzi F, Nogues MV & Boix E (2010) Eosinophil cationic protein aggregation: identification of an N-terminus amyloid prone region. Biomacromolecules 11, 1983-1990.
50. Pulido D, Moussaoui M, Nogués MV, Torrent M & Boix E (2013) Towards the rational design of antimicrobial proteins: single point mutations can switch on bactericidal and agglutinating activities on the RNase A superfamily lineage. FEBS J 280, 5841-5852.
51. García-Mayoral MF, Moussaoui M, de la Torre BG, Andreu D, Boix E, Nogués MV, Rico M, Laurents DV & Bruix M (2010) NMR structural determinants of eosinophil cationic protein binding to membrane and heparin mimetics. Biophys J 98, 2702-2711.
52. Joao HC & Dwek RA (1993) Effects of glycosylation on protein-structure and dynamics in ribonuclease-B and some of its individual glycoforms. Eur J Biochem 218, 239-244.
53. Williams RL, Greene SM & Mcpherson A (1987) The crystal-structure of ribonuclease-B at 2.5-a resolution. J Biol Chem 262, 16020-16031.
54. Wang FFC & Hirs CHW (1977) Influence of heterosaccharides in porcine pancreatic ribonuclease on conformation and stability of protein. J Biol Chem 252, 8358-8364.
55. Carsana A, Furia A, Gallo A, Beintema JJ & Libonati M (1981) Nucleic acid-protein interactions - degradation of double-stranded-Rna by glycosylated ribonucleases. Biochim Biophys Acta 654, 77-85.
56. Joao HC, Scragg IG & Dwek RA (1992) Effects of glycosylation on protein conformation and amide proton-exchange rates in Rnase-B. FEBS Lett 307, 343-346.
57. Rudd PM, Joao HC, Coghill E, Fiten P, Saunders MR, Opdenakker G & Dwek RA (1994) Glycoforms modify the dynamic stability and functional-activity of an enzyme. Biochemistry 33, 17-22.
58. Puett D (1973) Conformational studies on a glycosylated bovine pancreatic ribonuclease. J Biol Chem 248, 3566-3572.
59. Kim BM, Kim H, Raines RT & Lee Y (2004) Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. Biochem Biophys Res Commun 315, 976-983.
60. Helenius A & Aebi M (2001) Intracellular functions of N-linked glycans. Science 291, 2364-2369.
61. Hart GW & Copeland RJ (2010) Glycomics hits the big time. Cell 143, 672-676.
62. Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discovery 8, 226-234.
63. Sethuraman N & Stadheim TA (2006) Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 17, 341-346.
64. Wang LX & Lomino JV (2012) Emerging technologies for making glycan-defined glycoproteins. ACS Chem Biol 7, 110-122.
65. Peterson CG, Jornvall H & Venge P (1988) Purification and characterization of eosinophil cationic protein from normal human eosinophils. Eur J Haematol 40, 415-423.
66. Peterson CG, Eklund E, Taha Y, Raab Y & Carlson M (2002) A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 97, 1755-1762.
67. Carreras E, Boix E, Rosenberg HF, Cuchillo CM & Nogues MV (2003) Both aromatic and cationic residues contribute to the membrane-lytic and bactericidal activity of eosinophil cationic protein. Biochemistry 42, 6636-6644.
68. Torrent M, Sánchez D, Buzón V, Nogués MV, Cladera J & Boix E (2009) Comparison of the membrane interaction mechanism of two antimicrobial RNases: RNase 3/ECP and RNase 7. Biochim Biophys Acta 1788, 1116-1125.
69. Pulido D, Torrent M, Andreu D, Nogues MV & Boix E (2013) Two human host defense ribonucleases against mycobacteria, the eosinophil cationic protein (RNase 3) and RNase 7. Antimicrob Agents Chemother 57, 3797-3805.
70. Torrent M, Navarro S, Moussaoui M, Nogues MV & Boix E (2008) Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 47, 3544-3555.